Hanson Pharmaceuticals (03692): Xinyue® (inelizumab injection) was issued a drug registration certificate by the State Drug Administration for the second indication

Zhitongcaijing · 09/01/2025 14:49

Zhitong Finance App News, Hanson Pharmaceuticals (03692) issued an announcement. On August 26, 2025, the innovative drug Xinyue® (inelizumab injection) (this product) obtained a drug registration certificate issued by the China National Drug Administration (NMPA), which approved additional indications: suitable for adult patients with immunoglobulin G4 related diseases (IgG4-rd). This is the second indication approved by Xinyue®. This indication was included in the priority review and approval process by the NMPA on February 8, 2025.